Annotation Detail

Information
Associated Genes
ALK
Associated Variants
ALK EML4-ALK E6;A20
Associated Disease
lung non-small cell carcinoma
Source Database
CIViC Evidence
Description
Transduction of Ba/F3 cells with EML4-ALK variant 3a caused the cells to grow independently of IL3 addition. While incubation of Ba/F3 cells transduced with EML4-ALK variants 1 and 2 with Hsp90 inhibitor 17-DMAG caused cell death that was reversible with IL3 addition, Ba/F3 cells with variant 3a were not sensitized to 17-DMAG induced death, suggesting that 17-DMAG was effecting the EML4-ALK driver of IL3-independant proliferation. This in turn suggests that variant 3a may not rely on Hsp90 for stability in cancer cells to the extent of other variants.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1205
Gene URL
https://civic.genome.wustl.edu/links/genes/1
Variant URL
https://civic.genome.wustl.edu/links/variants/503
Rating
2
Evidence Type
Predictive
Disease
Lung Non-small Cell Carcinoma
Evidence Direction
Does Not Support
Drug
Alvespimycin
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
22912387
Drugs
Drug NameSensitivitySupported
AlvespimycinSensitivityfalse